DOUBLE-EXPRESSOR LYMPHOMA
Clinical trials for DOUBLE-EXPRESSOR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DOUBLE-EXPRESSOR LYMPHOMA trials appear
Sign up with your email to follow new studies for DOUBLE-EXPRESSOR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets 'Undruggable' cancer driver in Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can …
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Targeted attack on Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new two-step treatment for people with a high-risk, aggressive type of lymphoma who haven't had treatment yet. First, patients receive a targeted drug that seeks out and kills cancer cells, followed by a standard chemotherapy regimen. The goal is to see if…
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC